Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Karyopharm Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Progress

Karyopharm Therapeutics (KPTI) PT Raised to $22 at Baird; 'Expect a transformational year'

March 15, 2018 2:01 PM EDT

Baird raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $22.00 (from $15.00) while maintaining a Outperform rating.

Analyst Michael E. Ulz commented, "Recent progress across the selinexor franchise was highlighted, and management indicated initial commercial preparations are underway, a positive sign, in... More

Karyopharm Therapeutics (KPTI) PT Raised to $19 at Wedbush

March 15, 2018 1:57 PM EDT

Wedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $19.00 (from $18.00) while maintaining an Outperform rating.

Analyst David Nierengarten commented, "KPTI has a lot riding on STORM, with success opening the doors to near-term commercialization of selinexor for MM; we... More